Tuberculous meningitis: protracted course and clinical response to interferon-gamma

Lancet Infectious Diseases

Volumn 7, Issue 3, 2007, Pages 225-232

  Coulter, J Brian S ^a   Baretto, Richard L ^b   Mallucci, Connor L ^a   Romano, Maria I ^c   Abernethy, Laurance J ^a   Isherwood, David M ^a   Kumararatne, Dinakantha S ^d   Lammas, David A ^e  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHEMOKINE RECEPTOR CXCR4; CIPROFLOXACIN; CYTOKINE; DEXAMETHASONE; ETHAMBUTOL; ETHIONAMIDE; GABAPENTIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISONIAZID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PYRAZINAMIDE; RIFAMPICIN;

ALBUMIN BLOOD LEVEL; BLOOD BRAIN BARRIER; BRAIN VENTRICLE PERITONEUM SHUNT; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIZZINESS; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; FOLLOW UP; GENE EXPRESSION PROFILING; HEADACHE; HUMAN; HYDROCEPHALUS; LUMBAR PUNCTURE; NEUTROPHILIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SCHOOL CHILD; SYMPTOM; TUBERCULOMA; TUBERCULOUS MENINGITIS; UNITED KINGDOM; VOMITING;

ANTI-INFLAMMATORY AGENTS; ANTITUBERCULAR AGENTS; CEREBROSPINAL FLUID; CHEMOKINES; CHILD; DEXAMETHASONE; FEMALE; FEVER; GENE EXPRESSION; GLUCOSE; HUMANS; HYDROCEPHALUS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; NEUTROPENIA; TUBERCULOMA; TUBERCULOSIS, MENINGEAL;

EID: 33847074504     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(07)70054-3     Document Type: Review

References (58)

1. Humphries M., Teoh R., Lau J., et al. Factors of prognostic significance in Chinese children with tuberculous meningitis. Tubercle 71 (1990) 161-168
2. Ragno S., Romano M., Howell S., Pappin D., Jenner P., and Colston M. Changes in gene expression in macrophages infected with Mycobacterium tuberculosis: a combined transcriptomic and proteomic approach. Immunology 104 (2001) 99-108
3. Ganrot K., and Laurell C. Measurement of IgG and albumin content of cerebrospinal fluid and its interpretation. Clin Chem 20 (1974) 571-573
4. Reiber H., and Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 163 (1987) 319-328
5. Prabhakar S., Basha A., Bhagyalakshmi G., and Oommen A. Blood-brain-barrier and intrathecal immunoglobulin changes in tuberculous meningitis and demyelinating disorders: a preliminary report from a South Indian hospital. Acta Neurol Scand 81 (1990) 448-451
6. Sandyk R., and Seftel H. Dosage of anti-tuberculosis agents in tuberculous meningitis. SA Mediese Tydskrif 63 (1983) 222
7. Donald P., Gent W., Seifert H., Lamprecht J., and Parkin D. Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence for dosage and acetylation status. Pediatrics 89 (1992) 247-250
8. Parsons M. Tuberculous meningitis. Tuberculomas and spinal tuberculosis. A handbook for clinicians. 2nd edn. (1988), Oxford University Press, Oxford
9. Ellard G., Humphries M., and Allen B. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis 148 (1993) 650-655
10. Lincoln E., and Sewell E. Tuberculosis in children (1963), McGraw-Hill, New York 161-183
11. Miller F., Seal R., and Taylor M. Tuberculosis in children (1963), Churchill, London 395-422
12. Sumaya C., Simek M., Smith M., Seideman M., Ferriss G., and Rubin W. Tuberculous meningitis in children during the isoniazid era. J Pediatr 87 (1975) 43-49
13. Jeren T., and Beus I. Characteristics of cerebrospinal fluid in tuberculous meningitis. Acta Cytol 26 (1982) 678-680
14. Alarcón F., Escalante L., Pérez Y., Banda H., Chacon G., and Duenas G. Tuberculous meningitis: short course of chemotherapy. Arch Neurol 47 (1990) 1313-1317
15. Donald P., Schoeman J., Cotton M., and van Zyl L. Cerebrospinal fluid investigations in tuberculous meningitis. Ann Trop Paediatr 11 (1991) 241-246
16. Girgis N., Sultan Y., Farid Z., et al. Tuberculous meningitis, Abbassia Fever Hospital-Naval Medical Research Unit no. 3-Cairo, Egypt, from 1976 to 1996. Am J Trop Med Hyg 58 (1998) 28-34
17. Thwaites G., Nguyen D., Nguyen H., et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351 (2004) 1741-1751
18. Thwaites G., Simmons C., Quyen N., et al. Pathophysiology and prognosis in Vietnamese adults with tuberculous meningitis. J Infect Dis 188 (2003) 1105-1115
19. Ravenscroft A., Schoeman J., and Donald P. Tuberculous granulomas in childhood tuberculous meningitis: radiological features and course. J Trop Pediatr 47 (2001) 5-12
20. Chambers S., Hendrickse W., Record C., Rudge P., and Smith H. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet 2 (1984) 181-183
21. Teoh R., Humphries M., and O'Mahony G. Symptomatic intracranial tuberculoma development during treatment of tuberculosis: a report of 10 patients and review of the literature. QJ Med 63 (1987) 449-460
22. AbdulJabbar M. Paradoxical response to chemotherapy for intracranial tuberculoma: two case reports from Saudi Arabia. J Trop Med Hyg 94 (1991) 374-376
23. Afghani B., and Lieberman J. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis 19 (1994) 1092-1099
24. Doerr C., Starke J., and Ong L. Clinical and public health aspects of tuberculous meningitis in children. J Pediatr 127 (1995) 27-33
25. Reiser M., Fätkenheuer G., and Diehl V. Paradoxical expansion of intracranial tuberculomas during chemotherapy. J Infect 35 (1997) 88-90
26. Hejazi N., and Hassler W. Multiple intracranial tuberculomas with atypical response to tuberculostatic chemotherapy: literature review and a case report. Infection 25 (1997) 233-239
27. Awada A., Daif A., Pirani M., Khan M., Memish Z., and Al Rajeh S. Evolution of brain tuberculomas under standard antituberculous treatment. J Neurol Sci 156 (1998) 47-52
28. Rolinck-Werninghaus C., Kötz K., Magdorf K., Bunikowski R., Staab D., and Wakn U. Late clinical manifestation of cerebral tuberculomas in two children with tuberculous meningoencephalitis. Eur J Pediatr 160 (2001) 645-648
29. Nicolls D., King M., Holland D., Bala J., and del Rio C. Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis. Lancet Infect Dis 5 (2005) 795-801
30. Tandon P., and Bhargava S. Effect of medical treatment on intracranial tuberculoma-a CT study. Tubercle 66 (1985) 85-97
31. Schoeman J., van Zyl L., Laubscher J., and Donald P. Effect of corticosteroids on intracranial pressure, computed tomographic findings and clinical outcome in young children with tuberculous meningitis. Pediatrics 99 (1997) 226-231
32. Waecker N., and Connor J. Central nervous system tuberculosis in children: a review of 30 cases. Pediatr Infect Dis J 9 (1990) 539-543
33. Schoeman J., van Zyl L., Laubscher J., and Donald P. Serial CT scanning in childhood meningitis prognostic features in 198 cases. J Child Neurol 10 (1995) 320-409
34. Smith S., Jacobs R., and Wilson C. Immunobiology of childhood tuberculosis: a window on the ontogeny of cellular immunity. J Pediatr 131 (1997) 16-26
35. Flynn J., and Chan J. Immunology of tuberculosis. Annu Rev Immunol 19 (2001) 93-129
36. Fortune S., Solache A., Jaeger A., et al. Mycobacterium tuberculosis inhibits macrophage responses to interferon-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J Immunol 172 (2004) 6272-6280
37. Muhl H., and Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-gamma. Int Immunopharmacol 3 (2003) 1247-1255
38. Bronstein-Sitton N., Cohen-Daniel L., Vaknin I., et al. Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell funtion. Nat Immunol 4 (2003) 957-964
39. Harrington L., Hatton R., Mangan P., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
40. Schoeman J., Springer P., van Rensburg A., et al. Adjunctive thalidomide therapy for tuberculous meningitis: results of a randomised study. J Child Neurol 19 (2004) 250-257
41. Fu L., and Fu Liu C. Thalidomide and tuberculosis. Int J Tuberc Lung Dis 6 (2002) 569-572
42. Roberts M., Mendelson M., Meyer P., Carmichel A., and Lever A. The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports. J Infect 47 (2003) 251-255
43. Girgis N., Farid Z., Kilpatrick E., Sultan Y., and Mikhail I. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J 10 (1991) 179-183
44. Kumarvelu S., Prasad K., Khosla A., Behari M., and Ahuja G. Randomised controlled trial of dexamethasone in tuberculous meningitis. Tuber Lung Dis 75 (1994) 203-207
45. Prasad K., Volmink J., and Menon G. Steroids for treating tuberculous meningitis. Cochrane Database Syst Rev 3 (2000) CD002244.
46. Schoeman J., Elshof J., Laubscher J., Janse van Rensburg A., and Donald P. The effect of adjuvant treatment on serial cerebrospinal fluid changes in tuberculous meningitis. Ann Trop Paediatr 21 (2001) 299-305
47. Donald P., Schoeman J., Beyers N., et al. Concentrations of interferon gamma, tumor necrosis factor alpha and interleukin-1 beta in the cerebrospinal fluid in children treated for tuberculous meningitis. Clin Infect Dis 21 (1995) 924-929
48. Simmons C., Thwaites G., Quyen T., et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune response. J Immunol 175 (2005) 579-590
49. Mansour A., Frenck R., Darville T., et al. Relationship between intracranial granulomas and cerebrospinal fluid levels of gamma interferon and interleukin-10 in patients with tuberculous meningitis. Clin Diagn Lab Immunol 12 (2005) 363-365
50. Miyoshi Y., Noda S., Murai H., and Itoh H. Repeated deterioration of tuberculous meningitis due to a reduction in corticosteroid dosage during chemotherapy. Rinsho shinkeigaku 40 (2000) 1018-1022 (in Japanese).
51. Lammas D., Casanova J., and Kumararatne D. Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway. Clin Exp Immunol 121 (2000) 417-425
52. Holland S. Cytokine therapy of mycobacterial infections. Adv Intern Med 45 (2000) 431-452
53. Condos R., Rom W., and Schluger N. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet 349 (1997) 1513-1515
54. Giosues S., Casarini M., Ameglio F., et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 11 (2000) 99-104
55. Koh W., Kwou O., Suh G., et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 19 (2004) 167-171
56. Suarez-Mendez R., Garcia-Garcia I., Fernandez-Olivera N., et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis 4 (2004) 44
57. Raad I., Hachem R., Leeds N., Sawaya R., Salem Z., and Atwehs S. Use of adjunct treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin Infect Dis 22 (1996) 572-574
58. Seneviratne S., Doffinger R., Macfarlane J., et al. Disseminated Mycobacterium tuberculosis infection due to INF-γ deficiency. Response to replacement therapy. Thorax 62 (2007) 97-99